Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes (Paper June 15 2026)

Key Takeaways

• Lifestyle intervention cut multimorbidity risk by 21% vs placebo.
• Metformin showed no significant difference in multimorbidity risk.
• 21‑year follow‑up included 1,173 Medicare‑eligible participants.
• Hazard ratio for costly condition dyads dropped to 0.57 with lifestyle.
• Median participants developed five chronic conditions over study period.

Pulse Analysis

The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) have long been benchmarks for evaluating preventive strategies in high‑risk adults. By linking trial participants to Medicare claims over two decades, researchers could assess not just diabetes incidence but the broader emergence of chronic disease clusters, known as multimorbidity. This approach provides a rare, real‑world lens on how early interventions shape health trajectories well beyond the original study horizon.

Findings reveal that participants who received intensive lifestyle coaching—diet, exercise, and regular group sessions—experienced a 21% relative reduction in the risk of developing two or more chronic conditions compared with placebo. The adjusted hazard ratio of 0.79 indicates a statistically robust benefit, and the effect intensified (HR 0.57) when focusing on the most expensive disease pairings, such as cardiovascular disease and chronic kidney disease. In contrast, metformin, despite its proven efficacy in delaying diabetes, failed to demonstrate a meaningful impact on overall multimorbidity, suggesting that pharmacologic glucose control alone may not translate into broader health gains.

For policymakers and health systems, these results reinforce the economic and clinical case for investing in sustained lifestyle programs. The median participant accumulated five chronic conditions over the study period, highlighting the potential cost savings of preventing even a single condition. Scaling community‑based interventions, integrating them into Medicare Advantage plans, and aligning incentives for long‑term adherence could curb the rising tide of multimorbidity, improve quality of life for older adults, and alleviate pressure on the U.S. healthcare budget.